Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The extra step in NanoViricides, Inc. employed and patented mechanism makes it different from Clemsom's, right? What is your opinion?
Clemson researchers develop nanoparticle chicken feed is described as...
"...have built nanoparticles that mimic the host cell surface in poultry and locks to the targeted pathogens. The particles then bind together and are purged through the bowel. Tzeng calls it “intelligent chicken feed.” ~ Jeremy Tzeng and Clemson colleagues Fred Stutzenberger, Robert Latour Jr. and Ya-Ping Sun
“We have developed a small chemical ligand that mimics both the mammalian (or a-2,6-) and avian (or a-2,3) forms of the native sialic acid receptor of influenza viruses. We can design a nanoviricide to exhibit several ligands at a single point, and each nanomicelle may exhibit several hundred ligands on its small surface. The ligands are designed to look very much like (mimic) the sialic acid to the influenza viruses, and the high density of the ligands would force the virus to land onto the nanoviricide and get destroyed by the hidden ‘tails’ of the nanomicelle that snap out and merge into the viral surface lipid coat.” ~ Dr. Anil Diwan, PhD, President and Chairman of NanoViricides, Inc.
“We have clearly demonstrated that the design platform technology for nanoviricides allows development of powerful broad-spectrum antiviral drugs,” said Anil R. Diwan, PhD, President and Chairman of NanoViricides, Inc."
Consider becoming a long term investor. Next year will be a big year for NNVC (imho).
I figure you would ask the big question. I was right on that count:) Thanks for taking the time to investigate it.
FluCide for Humans will come first but in a not so distant future we may have an Avian FluCide that will be in the birds water supply.
Just to follow-up on the idea of "cides" for animals here is a 2008 article on chicken and nanoparticles:
DATE: February 21, 2008
CONTACT: Jeremy Tzeng, (864) 656-0239
tzuenrt@clemson.edu
WRITER: Peter Kent, (864) 650-7899
pkent@clemson.edu
Clemson researchers develop nanoparticle chicken feed
CLEMSON, S.C. — Poultry is big business in South Carolina and Clemson University scientists are using nanotechnology to keep the birds and consumers healthy.
Watch the videoThe researchers are developing drug-free ways to keep chickens and humans from contracting illnesses.
"If we use this physical purging, physical removal, we are not using antibiotics so the chance of the microorganism becoming resistant to it is really small,” Tzeng said.
Good question. Here are some recent news on a dog virus, the Circovirus.
Experts close in on dog virus; veterinarians say 'don't panic'
A mysterious, new canine virus that has popped up in various regions of Ohio is putting area dog owners on high alert. But veterinarians are cautioning them not to panic.
The canine virus has sickened eight dogs in Ohio since mid-August, killing four of them. The first four cases cropped up in Norwood, north of Cincinnati, where three of the dogs died after being kept at the same boarding facility.
A week later, four more dogs came down with the illness near Canal Fulton, between Akron and Canton, killing one.
source: http://www.mansfieldnewsjournal.com/article/20130911/NEWS01/309090044/Experts-close-dog-virus-veterinarians-say-don-t-panic-
"We are agnostic to the host...we don't care if you are a man, a mouse, a whale or a salamander, as long as you have a virus in your system, we destroy it."~ Dr. Eugene Seymour, CEO NanoViricides, Inc.
Wassup bro? Here's a bit of humor for all on this board as NNVC moves higher!
I disagree, but then I am vested on the success of this company. My opinion is obviously biased. I have seen NNVC progressively constructing a path to the clinical trials since 2011 when they contracted BCG for the preparation and submission of Investigational New Drug (IND) applications to the US FDA.
NanoViricides, Inc. (NNVC)is pioneering with their "transformational-technology". The US FDA is providing guidance beyond their documents. If injectable FluCide is not toxic then we only have to reach the human trials by mid-2014 and prove to the world we have an effective drug to effectively combat all strains of influenza, avoid the potentially fatal "cytokine storm" and progressively bring it to an end in a matter of hours, a day, two days.
You may want to read ZincFinger's posts 74459, 74460 and 74462 for more reasons as to why we should cut NanoViricides, Inc. some slack, now that they are on-track.
Once the "railway to the human trials" is complete with the first candidate, broad-spectrum injectable FluCide, the other candidates will roll down those tracks with greater ease, speed, through the human trials and FDA review to market. Confidence is high on Nanoviricides, Inc.!
"...we are a company...with the ability to rapidly create drugs, and when I say rapidly create drugs I'm talking about weeks instead of years..." ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.
"by the way, I'm sure that when you think human trials for drugs you think of hundreds of millions of dollars and years of time, well in this case because the disease only lasts a week, two weeks,...that it is possible to complete human trials in the space of a few short months...four parts to the human trials" ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.
Correction of my previous and fragmented statement.
I totally agree with your analysis which is very close, if not exact, to the time/events modeling you have been asserting on this board for some time. Thank you.
Given that these things are written very conservatively and therefore going with 12 months from the end of the reporting period in June, that would put us at June of 2014 to have tox completed (and presumably reported).
he, he, he...good one!
Nanovircides, Inc.(NNVC) is "laying down tracks for a railway" to market. There is currently a temporary delay in the construction of the "railway to market". The reason,
What's been misinterpreted as a problem is actually a very major accomplishment for the technology: the toxicity is SO low that they need much larger amounts for testing. In tox studies you test until you get some indications of toxicity because you have to know what the symptoms and effects of toxicity are, otherwise you don't know what to watch for. ~ ZincFinger
Merck also said it will develop some of those candidates by investing in strengthening its pipeline through new licensing and business development activities with external partners; as well as concentrate in 10 "prioritized" national markets that account for most of its pharmaceutical and vaccine revenues – the U.S., Brazil, Canada, China, France, Germany, Japan, Korea, Russia, and the U.K. ~ nanopatent post
"...we are a company...with the ability to rapidly create drugs, and when I say rapidly create drugs I'm talking about weeks instead of years..." ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.
"by the way, I'm sure that when you think human trials for drugs you think of hundreds of millions of dollars and years of time, well in this case because the disease only lasts a week, two weeks,...that it is possible to complete human trials in the space of a few short months...four parts to the human trials" ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.
Your inference from the excerpt directly contradicts the excerpt published on marketwatch.com Aug 19, 2013...
The Company has also started sub-kg scale production of our injectable FluCide(TM) anti-influenza drug candidate at its current facility. Safety and toxicology studies of our injectable and oral FluCide drugs are estimated to require very large quantities of the drugs, because of strong safety data evidenced from our in vivo (animal) efficacy studies to date. The Company will be able to initiate GLP Safety/Toxicology studies ("Tox Package") studies of our injectable FluCide drug when the requisite large amount of drug substance is produced.
Tomorrow we get to test the resilience of NNVC. I hope we open at $5.29/s, close with a higher low and back to the upward trend.
Excellent story on advanced science and how it will benefit mankind! The Nanoviricides, Inc. Train will soon be leaving to a station closer to that 23rd Century future...
Duke researchers had been working on this for 10 years and had just received permission from the FDA to treat 10 patients, but for only one a month. (A Duke press release last May explained that the treatment was designed to capitalize “on the discovery that cancer cells have an abundance of receptors that work like magnets in drawing the poliovirus, which then infects and kills the cells. The investigational therapy uses an engineered form of the virus that is lethal to cancer cells, while harmless to normal cells. The therapy is infused directly into a patient’s tumor. The virus-based therapy also triggers the body’s immune system to attack the infected tumor cells.")
Its name is DAVEI - which stands for “Dual Action Virolytic Entry Inhibitor”- and it can pull a fast one on HIV. DAVEI was invented and tested by scientists from Drexel’s College of Engineering; School of Biomedical Engineering, Science and Health Systems; and College of Medicine, and is the latest in a new generation of HIV treatments that function by specifically destroying the virus without harming healthy cells.
In addition to the incentives related to orphan drug status, the Company may be eligible to receive a Priority Review Voucher (PRV) in the USA, upon approval of a drug against dengue viruses. A PRV can be applied by the Company to another drug candidate to obtain a “priority review” to speed up the regulatory process for that other drug. A PRV can also potentially be sold to another pharmaceutical company to obtain an immediate financial benefit. The value of a PRV has been variously estimated to be between $200M to $600M for such transactions. ~ fool.com
We have a good company in NanoViricides, Inc., eager to deliver its "transformational-technology" therapeutic drugs to the market, therapeutic drugs that will make healthcare more effective, and affordable. In the new beginning, anyone that has a flu virus will go to a clinic to be diagnosed and prescribed/administered a broad-spectrum FluCide that will end the virus in a day or two. For example, a patient with SARS will not have to spend a week or two in the hospital intensive care unit. It would be quite a difference form the healthcare we have today.
Likewise, the people should not ignore the national debt because it is a path to repeat Detroit's mistakes but on a larger scale. Watch/listen video on Detroit's recent bankruptcy including debt, unfunded pensions, health care liabilities, legalities, unemployment, income, poverty, tax burden, education, police, crime, white flight, racial divide, corruption, more bankruptcies coming, bailouts, and comparisons to the United States economy.
I was looking for the significance of no NNVC After Hours Trading (AHT) and found this http://www.ehow.com/about_6583096_significance-after-market-stock-prices.html
NNVC is not settled yet on the new exchange, NYSE MKT LLC. The reward is not worth the risk, at least for now. Thanks.
NanoViricides, Inc. is advancing its oral broad-spectrum anti-influenza drug candidate, NV-INF-2, towards IND-enabling studies. This may be the first ever nanomedicine drug of any kind that is active when administered orally. This drug is being developed for out-patient influenza cases, and may also be useful for influenza prophylaxis, as in use for the protection of health care workers.
In addition, the Company continues to develop its injectable anti-influenza drug, NV-INF-1, towards IND-enabling studies. This drug candidate has much greater activity than the oral drug, and is intended for use in hospitalized patients with influenza or potentially influenza-like illness. The Company believes it will be useable in immuno-compromised populations, and may receive an orphan drug classification for this indication. Both of these drugs in the anti-influenza FluCide™ program have demonstrated very high effectiveness in a lethal influenza animal model, routinely showing substantial superiority to oseltamivir (Tamiflu®), the current standard of care. The Company believes that these drugs will be useable against most if not all types of influenza viruses, including seasonal (such as H1N1, H3N2), epidemic (such as H1N1/2009 “swine flu”, H3N2/2012), novel strains such as H7N9 that is currently circulating in China, and bird flu (such as H5N1, various clades). In addition, both of these drugs have shown extremely good safety profile in all of the animal studies that have been performed to date. This strong safety profile has necessitated a substantial scale-up in the Company’s current synthesis capabilities prior to commissioning a formal GLP safety and toxicology (“Tox Package”) study. The Company is in the process of developing the necessary scale-up synthesis laboratory.
==================================================================================================================
A cGMP manufacturing capability is projected to be soon complete/integrated (4Q 2013) for these and other nanoviricides drug candidates.
==================================================================================================================
The Company previously held a pre-IND meeting with the US FDA for its anti-influenza drug candidate, NV-INF-1, in the FluCide program on March 29, 2012. The Company believes it has received valuable input from the US FDA, applicable to the development of its anti-influenza drug candidates.
With the current strong cash position, the Company believes that it has sufficient funds available to perform the necessary IND enabling studies for its anti-influenza drug programs, to file an Investigational New Drug Application (“IND”) with the US FDA, and to conduct initial human clinical trials of its first anti-influenza drug.
Including the Flucide program, the Company currently has six commercially important drug candidates in its pipeline. These include the aforementioned drugs against all Influenzas, HIVCide™, HerpiCide™, DengiCide™, and a broad-spectrum nanoviricide eye drop formulation against viral infections of the eye. These programs are based on the Company’s platform technology that enables specifically targeting a particular type of virus with a novel mechanism of action. In addition, the Company continues its other research and development programs. These include (a) broad-spectrum nanoviricides against a number of Neglected Tropical Diseases, and (b) its novel ADIF™ (“Accurate Drug In Field”™) technologies which promise a way to attack novel viruses, whether man-made (bioterrorism) or natural (such as SARS), before they cause a pandemic.
source: http://www.nanoviricides.com/press%20releases/NanoViricides%20Files%20Quarterly%20Report%20-%20Reports%20Having%20Sufficient%20Funds%20and%20Satisfactory%20Progress%20in%20its%20Advancing%20Pipeline.html
What is the significance of no one trading NNVC after hours? Thx.
Excellent,..we will be banking on it as pps moves higher! I saw a post of $25/s by Christmas. Higher bids, anyone? :)
They do have room for expansion at the Shelton facility and Dr. Seymour in the past has indicated a preference for going it alone. We shall see...
Excerpt from Today's PR...keeping an eye on the prize
NanoViricides Begins Trading on NYSE MKT National Exchange; CEO Dr Seymour Invited to Speak at Duke University’s Fuqua Business School
WEST HAVEN, Conn.--(BUSINESS WIRE)--
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), announced today that its stock began trading today on the NYSE MKT National Exchange under its original symbol, NNVC.
In another Company news, our CEO, Eugene Seymour, MD, MPH, is invited to speak at the Duke University Fuqua School of Business today afternoon. His talk will focus on policies that can help accelerate the development of pharmaceuticals against diseases that pharma companies would otherwise not have much interest in, or “orphan drug” development.
The concept of the Priority Review Voucher (PRV) was initially developed by three professors, David Ridley, Jeff Moe and Henry Grabowski at the Fuqua School of Business of the Duke University. Dr. Ridley invited Dr. Seymour to speak on the importance of economic incentives to help innovative pharmaceutical companies attach higher priorities to drug development programs against “orphan” diseases.
The Priority Review Voucher concept that the professors developed was embraced by the US FDA. Currently, the US FDA’s list of diseases for which no adequate therapy exists that are eligible for a PRV contains about 16 diseases. Dengue is at present the only viral disease on the list. The existence of the PRV was an important factor in the Company’s decision to assign a high priority to its dengue drug development program.
source: http://finance.yahoo.com/news/nanoviricides-begins-trading-nyse-mkt-133500014.html
In addition to the incentives related to orphan drug status, the Company may be eligible to receive a Priority Review Voucher (PRV) in the USA, upon approval of a drug against dengue viruses. A PRV can be applied by the Company to another drug candidate to obtain a “priority review” to speed up the regulatory process for that other drug. A PRV can also potentially be sold to another pharmaceutical company to obtain an immediate financial benefit. The value of a PRV has been variously estimated to be between $200M to $600M for such transactions.
We have "good news" coming, here and abroad!
Now, that is what I would call a fast development of broad-spectrum FluCide. Can't get any faster than that.
Once broad-spectrum FluCide gets FDA review and approval for market, in the event of a need to develop/optimize more for new mutant/strain of Influenza, how long would it take to get a new broad-spectrum FluCide through FDA review? A month? Two months?
6 August 2009 | GENEVA - It takes approximately five to six months for the first supplies of approved vaccine to become available once a new strain of influenza virus with pandemic potential is identified and isolated. These months are needed because the process of producing a new vaccine involves many sequential steps, and each of these steps requires a certain amount of time to complete.
source: http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090806/en/index.html
"...we are a company...with the ability to rapidly create drugs, and when I say rapidly create drugs I'm talking about weeks instead of years..." ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc
"by the way, I'm sure that when you think human trials for drugs you think of hundreds of millions of dollars and years of time, well in this case because the disease only lasts a week, two weeks,...that it is possible to complete human trials in the space of a few short months...four parts to the human trials" ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.
This is a good bit of information that adds detail, specially that Feb 15, 2010 Additional License Agreement with TheraCour Pharma, Inc.. Thx Puffer.
So even though this 47% short weight is common, NNVC manages to move up by $0.73 (13%+) on a day when the DOW is down 49! Can't wait to see what it is like once on the NYSE MKT LLC!
Thank you BigKahuna for your concise reply.
I do not know about the contract between TheraCour and Nanoviricides, Inc. but what if it is exclusive and not transferable. In other words, any entity trying to acquire Nanoviricides, Inc. must also deal with TheraCour Inc.. Is this possible?
another_voice_2...I hope you get your shares added soon. From what I read you think there could be a mighty jump in pps any given morning. There are known catalysts and Milestones coming our way this 4Q 2013. And then there is the unknown, but I still believe the unknown could be good. Nanoviricides, Inc. has been preparing for this time for years and they have professional entities managing their advance towards the human trials mid-2014.
I read resistance level at $6.08 and after that I see no info on resistance levels listed. EW may offer other information.
Thanks for sharing the info. I do enjoy when all traders here post two or three lines describing hour to hour progress. Believe when I say it seems like a "Secretariat" race, way in front and not much to say about others. Best to you and all that post here!
From today's announcement and past ihub posts come the advantages of being in the NYSE MKT LLC, superior price discovery, reduced trading volatility and added liquidity. DOW dropped today 49 points.
NYSE MKT is considered a premier US equities market for listing and trading of small growth companies. NYSE MKT is a fully integrated trading venue within the NYSE Euronext community and leverages the NYSE's advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE Euronext community.
If we have a net move up of $0.80/day for 30 days, between now and December 30, 2013, we will be sitting at $24/s. Nothing wrong with being conservative.
JG36...You replied with a rhetorical (question + Petri) but that is OK. Belief or not, Nanoviricides, Inc. has been moving, training, pushing boundaries for years for that date, September 25 2013, when it is officially on the "Big Board". There is another marker, "tox studies initiated" that will lead to deliverables, projected Milestone "tox studies" initial results (2013). BASi designed the "tox studies" based on the pre-IND meeting, along with its sponsor Nanoviricides, Inc., and with the guidance from the US FDA. Moreover, these memorable quotes tell me...
“We are rapidly advancing towards our goal of filing an IND with the FDA for Influenza based on the guidance we received in our previous pre-IND meeting with the FDA,” said Anil R. Diwan, President of the Company.
As has been pointed out repeatedly here, Diwan and crew have at least one FDA workshop where they presented early findings and received feedback on what animal studies need to be performed. Also, through several NNVC associates--Barton and Fields are good examples of people who have contacts within the FDA--Diwan et al have been in regular contact. So, the assumption that these decisions to continue testing and the time to compile a submission are all done in a vacuum is simply not true. ~ BigKahuna
The Company (Nanoviricides, Inc.) anticipates that it will need very large quantities of the drug candidate for these "tox package" studies. The Company has found FluCide to be safe in animals at large dosages, and will need to determine certain safety and toxicology limit parameters. ~ Marketwatch.com
The Company believes that it has received valuable guidance from the US FDA in this meeting. We believe that the guidance we received goes beyond FDA guidance documents, and is more specific for our drug candidate, NV-INF-1. The Company will now plan and execute the studies identified based on this meeting. ~ Businesswire
I'm pretty sure that the MTA is already effective. The question now is how long will it take to develop an anti-MERS and ANTI-H7N9 viricide, and send the materials to start the testing? Has Diwan and crew already developed one or both? If not, how long might it take? 3 to 8 weeks? ~ BigKanuna
IMO, the biggest thing, Anil was able to develop the MERS solution in less than a week. Less than a week for the type that will be tested in EU is pretty amazing and beats the 3 weeks of the rapid in field technology they previously talked about. ~ BigKanuna
"...we are a company...with the ability to rapidly create drugs, and when I say rapidly create drugs I'm talking about weeks instead of years..." ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.
"by the way, I'm sure that when you think human trials for drugs you think of hundreds of millions of dollars and years of time, well in this case because the disease only lasts a week, two weeks,...that it is possible to complete human trials in the space of a few short months...four parts to the human trials" ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.
Correction...Batches (plural) has to do with cGMP. NanoViricides, Inc. is not there yet but it will be 1H 2014, soon.
JG36...I had a question and you take upon yourself to reply with...another question??? Never mind. Batches (plural) has to do with cGMP. NanoViricides, Inc. is not there yet but it will be 4Q 2013, soon. Those cGMP batches will be identical (tight tolerances).
"The Company will be able to initiate GLP Safety/Toxicology studies (“Tox Package”) studies of the injectable FluCide drug when the requisite large amount of drug substance is produced." That may have happened already and I speculate released to us along with a "big board" announcement.
Announcing that "tox studies" have begun, all by itself, only indicates that the "train is moving" on-track to deliver, as expected, positive toxicology "initial results" on injectable FluCide, 4Q 2013. And that would be that.
When the cGMP plant is completely integrated, the batch of candidate drug product to be used in the human trials will likely be the same as that used in the toxicology studies. NanoViricides, Inc. will be making identical batches of that injectable FluCide.
I therefore think we are now waiting for the up-list to the "big board" NYSE MKT LLC PR, which I believe will also include a statement that "GLP Safety/Toxicology studies (“Tox Package”) studies of the injectable FluCide drug were initiated..." and then we are off to the races! I am speculating, and vested with NNVC. I'm trying to persuade others to join in. I enjoy reading posts here, even persuasive contrarian ones.
But then, Nanoviricides, Inc. may still announce "Tox" studies "began in ..." because of the sentence in "bold"...it is still an event that is conducted by BASi with the "injectable FluCide" drug produced/supplied.
The Company will be able to initiate GLP Safety/Toxicology studies (“Tox Package”) studies of the injectable FluCide drug when the requisite large amount of drug substance is produced.
I believe batches of drug substance are continuously being produced, shipped and seamlessly the "Tox studies" have begun. Perhaps someone posting here, that has worked in a lab (GLP), may confirm this is possible. I'm speculating here. Nanoviricides, Inc. will nevertheless include this in a PR because it is an ongoing process that leads to an important catalyst, "initial results". Monday is only hours away. Best to all!
Indeed I do buy Nanotoday's point.
I don't believe announcing that tox testing has begun will have any material impact on the SP. Announcing results, yes. (now if they have been conducting tox then they could announce results by year's end...but that's all the way full thinking) ~ Nanotoday at investorshub.com
I meant to post this video but missed it!
Blzzy...what happened with this board's favorite horse today, NNVC? It was trying to get out of the "starting gate" but would not get too far. The handlers would get the horse back behind the gate. Perhaps because the up-list is not official yet. Is it six days to make it official? We'll see, Monday is coming. Have a great weekend!
"The idea behind DAVEI was to design a molecule that hijacks the virus’s fusion machinery, the tools it uses to attach to and attack a healthy cell, and trick the virus into destroying itself. HIV invades a healthy cell by first attaching via protein “spikes” that then collapse to pull viral and cell membranes together, fusing them and allowing the genetic contents of the virus to enter the healthy cell. The cell is rewired by the viral genetic material into producing more viruses instead of performing its normal function, which, in the case of cells infected by HIV, involves normal immunity. AIDS is the result."
“For lack of a better term, DAVEI ‘tricks’ the virus into ‘thinking’ it is about to infect a healthy cell, when, in fact, there is nothing there for it to infect,” Abrams said. “Instead, it releases its genetic payload harmlessly and dies.”
The DAVEI molecule is comprised of two pieces: Membrane Proximal External Region (MPER) and cyanovarin (CVN) which allows it to attach to both the viral membrane and the protein spike of the virus. This allows DAVEI to make the virus behave as if it's attached to a healthy cell.
If I understand this mechanism correctly, the pop of the virus structure is normal once inside the cell but what is not normal is that when attached to DAVEI the virus is tricked (transfers control to EXIT) to pop open outside a cell where it releases its genetic material and is rendered harmless.
In the case of Nanoviricides, Inc., the virus structure attaches to the nanoviricide, the nanoviricide opens up and the lethal "hidden tails" cover the virus particle lipid coat and destroys it rendering it harmless.
DAVEI may be competition years down the road but once Nanoviricides, Inc. reaches the market and proves to be effective the other may not get too far. Too early to say with certainty though. We will continue with the "transformational technology" of Nanoviricides, Inc., keep an eye on the competition and time will tell if their "wheel" is good enough or better than Nanoviricides, Inc. "wheel". You are vested in the success of Nanoviricides, Inc. like many of us are here, and I believe you have agreed that time is on the side of Nanoviricides, Inc., as the Rolling Stones say,...have a great weekend!
To some this is old news but to some newcomers it is simply "news." Even those that have been posting on this board for sometime may find some information they may have missed by re-posting "old" news. It is definitely information that may help the newcomer/small investor do their own research. They can then proceed to invest with the "good people" of NanoViricides, Inc..
I think the aforementioned will also satisfy Echo20's question.
It looks like NNVC is being held "at the starting gate" today until up list becomes official. Have a good day!
NanoViricides, Inc. projected Milestones (2013-2014)
-cGMP/R&D Center Shelton CT integration completes ~ 4Q 2013
-Equipment moved into new cGMP plant ~ 4Q 2013
-Commision new cGMP plant (3 identical test batches)~ 1H 2014
-Receive initial results toxicology studies FluCide ~ 4Q 2013
-Prepare IND for submission to regulatory authorities ~ 4Q 2013
I understand what you say. This needed editing, now it is done.